(Q35076713)

6 August 2017

1 reference

title

Gene therapy ethics and haemophilia: an inevitable therapeutic future? (English)

1 reference

6 August 2017

0 references

0 references

0 references

Dimichele D

1

1 reference

6 August 2017

Miller FG

series ordinal

2

1 reference

6 August 2017

Fins JJ

series ordinal

3

1 reference

6 August 2017

publication date

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

145-152

1 reference

Hemophilia. After a setback, gene therapy progresses...gingerly

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Gene therapy for the haemophilias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

A tumultuous year for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Excitement in gene therapy!

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Altering the pathway to human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Long-term outcome of individualized prophylactic treatment of children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Barriers to compliance with prophylaxis therapy in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

The use of central venous catheters (portacaths) in children with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Ethics of haemophilia care in the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Interventions in the human genome: some moral and ethical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Human germline gene therapy reconsidered

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Intrauterine correction of factor VIII (FVIII) deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Policy forum: human genetics. Ethical considerations in leaping from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Progress in haemophilic care: ethical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Harm, ethics committees and the gene therapy death

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Human gene therapy: the good, the bad, and the ugly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Disability, gene therapy and eugenics--a challenge to John Harris

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Hemophilia treatment. An introduction to gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Gene therapist, heal thyself

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Changing roles for academia and industry in genetics and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Clinical medicine. FDA to release data on gene therapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Policy statement of the American Society of Gene Therapy on reporting of patient adverse events in gene therapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Ombudsman or hotline for Gene therapy clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Rewriting the "points to consider": the ethical impact of guidance document language

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

21 January 2018

Gene therapy on the RAC.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Gene therapy and jurisprudence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Fifteen-year follow up for gene therapy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Gene therapy for rare diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

Adverse event reporting: essential for science and public trust

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00725.X

10.1046/J.1365-2516.2003.00725.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference